- Home
- NPV vs CATX Comparison
NPV vs CATX Comparison
Compare NPV & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NPV | CATX |
|---|---|---|
| Founded | 1993 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.1M | 211.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NPV | CATX |
|---|---|---|
| Price | $11.04 | $2.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $11.56 |
| AVG Volume (30 Days) | 38.9K | ★ 1.4M |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 3.90% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,075,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.92 | $1.60 |
| 52 Week High | $11.55 | $5.39 |
Technical Indicators
Market Signals| Indicator | NPV | CATX |
|---|---|---|
| Relative Strength Index (RSI) | 36.73 | 53.90 |
| Support Level | $10.99 | $2.67 |
| Resistance Level | $11.30 | $2.88 |
| Average True Range (ATR) | 0.10 | 0.19 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 13.78 | 64.44 |
Price Performance
Historical ComparisonAbout NPV Nuveen Virginia Quality Municipal Income Fund
Nuveen Virginia Quality Municipal Income Fund is a diversified closed-end management investment company. The fund seeks to provide current income exempt from both regular federal and designated state income taxes. The fund invests in a portfolio of municipal obligations issued by state and local government authorities. Company mostly invest in Education and Civic Organizations, Tax Obligation/General, Healthcare, Utilities , Housing/Multifamily, Transportation, and Others.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.